On the contrary, one randomized trial, initially aimed to investigate the effect of low-dose Tamoxifen and Fenretinide on breast cancer risk, found an inverse association between adiponectin levels and breast cancer risk [HRper unit increase = 0.88 (.081–0.96) [26]]. This evidence concerns the gene ADIPOQ and breast cancer.